Monday, May 12, 2025
Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Moving Forward. MariMed brands continue to capture more share across the markets served. The Company expanded into 70 new storefronts in the quarter. Although MariMed’s brands are already top sellers in their markets, we believe there is a significant opportunity to seize additional market share.
1Q25. Revenue in the first quarter of 2025 of $38 million was virtually unchanged from the first quarter of 2024. We had projected $38.8 million. Adjusted EBITDA was $2.56 million, down from $4.66 million last year. Reported net loss was $5.4 million, or $0.01/sh, compared to a net loss of $1.3 million, or breakeven, last year.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
